Hemostemix Inc. is a clinical-stage biotechnology company based in Calgary, Canada, focused on developing, manufacturing, and commercializing blood-derived cell therapies for various medical conditions. The company utilizes a non-invasive approach by creating cell therapy products from the patient’s own blood. Its lead product, ACP-01, is an autologous cell therapy currently undergoing Phase II clinical trials for the treatment of critical limb ischemia, among other ischemic conditions. In addition to ACP-01, Hemostemix is developing a range of synergetic cell populations, including bone cell precursors, myocardial cell precursors, and neural cell precursors, aimed at addressing vascular diseases and improving patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.